Capital has made over 1 trades of the Zosano Pharma Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital sold 88,281 units of ZSAN stock worth $741,560 on 26 February 2018.
The largest trade Capital's ever made was selling 88,281 units of Zosano Pharma Corp stock on 26 February 2018 worth over $741,560. On average, Capital trades about 88,281 units every 0 days since 2018.
You can see the complete history of Capital Kaz stock trades at the bottom of the page.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L..., and Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: